Continue working to secure enactment of the bipartisan bill preventing future deadly TB outbreaks.

John R. Moolenaar · Michigan · Republican

policy impact 0.74 specificity 0.87 extraction confidence 98%

Contest this claim

Occurrences

I will continue my work in Congress to ensure this commonsense legislation is signed into law,

Moolenaar commits to keep working until the TB-prevention bill becomes law.

Health Care | Congressman John Moolenaar
primary · other · model gpt-5.4-mini

I will continue my work to make it law to prevent future deadly TB outbreaks," said Moolenaar.

Moolenaar reiterates his commitment to enact the TB-prevention legislation.

Health Care | Congressman John Moolenaar
primary · other · model gpt-5.4-mini

I will continue my work in Congress to ensure this commonsense legislation is signed into law

Moolenaar committed to continuing his work in Congress to secure enactment of the Shandra Eisenga Human Cell and Tissue Product Safety Act, which aims to prevent tuberculosis infections from contaminated bone graft tissue by requiring screening and accountability for tissue suppliers.

Moolenaar, Dingell Legislation to Stop Deadly TB Outbreaks Passed by House | Congressman John Moolenaar
secondary · other · model gpt-5.5

Evidence

Latest Action: Senate - 06/24/2025 Received in the Senate and Read twice and referred to the Committee on Health, Education, Labor, and Pensions. Tracker: This bill has the status Passed House. House action on 06/23/2025 was agreed to by voice vote under suspension of the rules.

The bipartisan bill advanced in the House and was sent to the Senate, but no enactment is shown; it remains pending in Senate committee.

partial same_term A for effort

Actions - H.R.1082 - 119th Congress (2025-2026): Shandra Eisenga Human Cell and Tissue Product Safety Act | Congress.gov | Library of Congress
secondary · model gpt-5.4-mini · confidence 99%

Contest this evidence item

The bill was introduced by Rep. Moolenaar on 02/06/2025. The latest summary describes it as establishing civil penalties, FDA workshops, a public docket, reporting to Congress, and educational materials to prevent tissue-related TB outbreaks; related bill H.R.340 is listed as a same-congress related measure.

Confirms the specific bipartisan prevention bill and its active status in the 119th Congress, but does not show enactment into law.

partial same_term A for effort

All Info - H.R.1082 - 119th Congress (2025-2026): Shandra Eisenga Human Cell and Tissue Product Safety Act | Congress.gov | Library of Congress
secondary · model gpt-5.4-mini · confidence 95%

Contest this evidence item

Today, Congressman John Moolenaar and Congresswoman Debbie Dingell’s bipartisan legislation, the Shandra Eisenga Human Cell and Tissue Product Safety Act, was unanimously passed by the House of Representatives.

Shows Moolenaar took a concrete step toward enactment by securing House passage of the bill; the release itself does not indicate final enactment.

partial same_term A for effort

Moolenaar, Dingell Legislation to Stop Deadly TB Outbreaks Passed by House | Congressman John Moolenaar
secondary · model gpt-5.4-mini · confidence 98%

Contest this evidence item

The bipartisan legislation was passed by the House of Representatives on December 16, 2024, and was introduced in response to a tuberculosis-related death and outbreak concerns.

Earlier House passage shows the campaign effort had already achieved one chamber, but still not final enactment.

partial same_term A for effort

House Passes Dingell, Moolenaar Bill to Prevent Deadly TB Outbreaks | Congresswoman Debbie Dingell
secondary · model gpt-5.4-mini · confidence 93%

Contest this evidence item

Assessments

partial same_term A for effort

Moolenaar clearly continued working on the bipartisan TB-outbreak-prevention bill by introducing/co-leading the measure and advancing it through the House, including unanimous House passage in June 2025. However, the promise was to secure enactment, and the evidence shows the bill was only passed by the House and then referred to the Senate committee, with no final enactment into law shown. Because he made a substantial legislative effort and achieved meaningful progress short of enactment, this is partial rather than delivered.

provider openai · model gpt-5.4 · confidence 98%